复发难治性非霍奇金氏淋巴瘤的DHAP方案治疗疗效观察.docVIP

精品论文 参考文献 复发难治性非霍奇金氏淋巴瘤的DHAP方案治疗疗效观察 郴州市第一人民医院中心医院 湖南郴州 423000 【摘 要】目的：观察DHAP方案治疗复发难治性非霍奇金氏淋巴瘤的疗效及安全性。方法：选择我科收治的36例复发难治性非霍奇金淋巴瘤患者，将所有研究治疗第1d予以顺铂85mg/ cm2，在避光的条件下行静脉滴注，同时予以阿糖胞苷2g/m2，12h /次，静脉滴注；在治疗第1-4d予以地塞米松40mg/d，静脉滴注。观察治疗后患者的疗效，并进行安全性评价。结果：所有患者均完成2个治疗周期后进行疗效及安全性评定，其中36例患者中CR者12例、PR者12例、NC者10例、PD者2例，有效率66.7%；不良反应以血液系统毒性为多，其中贫血者8例、血小板降低者7例以及白细胞减少者7例，共计61.1%。与治疗前比较，治疗后患者的SAS评分均降低明显，FACT评分中PWB、SWB、EWB、FWB评分均增加明显，差异具统计学意义（Plt;0.05）。结论：DHAP方案治疗复发难治性非霍奇金氏淋巴瘤疗效较好，安全性尚可，可较好的改善患者的焦虑情绪，提高生活质量。 【关键词】复发难治性；非霍奇金氏淋巴瘤；DHAP方案；疗效；安全性 Observation on curative effects of DHAP scheme in treatment of recurrent refractory non-Hodgkinrsquo;s lymphoma Zhu Pingrsquo;an （Chenzhou Center Hospital（First Peoplersquo;s Hospital），Hunan Chenzhou，423000） [Abstract] Objective：To observe the curative effects and safety of DHAP scheme in treatment of recurrent refractory non-Hodgkinrsquo;s lymphoma.Methods：36 patients with recurrent refractory non-Hodgkinrsquo;s lymphoma were selected from our department.All of the patients were given 85mg/cm2 cisplatin via intravenous drip in the dark on the first day of treatment，while the patients were given 2g/m2 cytarabine via intravenous drip，12h each time.The patients were given 40mg/d desamethasone via intravenous drip on 1-4d of treatment.Patientsrsquo; curative effects were observed and were given safety evaluation.Results：All patients completed 2 treatment courses and were given evaluation on curative effects and safety.Among 36 patients，CR results were in 12 cases，PR in 12 cases，NC in 10 cases，and PD in 2 cases，with effective rate of 66.7%；adverse reaction was given priority to toxicity of blood system，including 8 cases of anemia，7 cases of decreased platelet and 7 cases of leucopenia，a total of 61.1%.Compared with before treatment，SAS scores were significantly decreased in patients after treatment，but scores PWB，SWB，EWB，and FWB in FACT scale were significantly increased，with statistically significant difference（Plt;0.05）.Conclusion：DHAP scheme is effe